BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 17107388)

  • 1. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
    Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
    Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
    Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
    Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
    Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
    Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab restores the balance between pro- and anti-apoptotic proteins in regressing psoriatic lesions.
    Kokolakis G; Giannikaki E; Stathopoulos E; Avramidis G; Tosca AD; Krüger-Krasagakis S
    Br J Dermatol; 2012 Mar; 166(3):491-7. PubMed ID: 21985184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
    Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
    Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study.
    Abdou AG; Hanout HM
    J Cutan Pathol; 2008 May; 35(5):445-51. PubMed ID: 18005174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
    Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study.
    Simonetti O; Lucarini G; Bernardini ML; Simoncini C; Biagini G; Offidani A
    Br J Dermatol; 2004 May; 150(5):940-8. PubMed ID: 15149507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of infliximab on keratinocyte apoptosis in psoriasis patients.
    Raho G; Vena GA; Bizzoca A; Cassano N; Garofalo E; Congedo M; Gennarini G
    Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):227-31. PubMed ID: 20507213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas.
    Zhen HN; Zhang X; Hu PZ; Yang TT; Fei Z; Zhang JN; Fu LA; He XS; Ma FC; Wang XL
    Cancer; 2005 Dec; 104(12):2775-83. PubMed ID: 16284993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
    Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
    Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells.
    Chen XM; Luan XY; Lei DP; Ma XJ; Liu XX; Liu J; Pan XL
    ORL J Otorhinolaryngol Relat Spec; 2008; 70(3):168-75. PubMed ID: 18391576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
    J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma.
    Kreuter A; Hyun J; Skrygan M; Sommer A; Bastian A; Altmeyer P; Gambichler T
    Br J Dermatol; 2006 Sep; 155(3):600-7. PubMed ID: 16911288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.
    Johansen C; Vinter H; Soegaard-Madsen L; Olsen LR; Steiniche T; Iversen L; Kragballe K
    Br J Dermatol; 2010 Dec; 163(6):1194-204. PubMed ID: 20846304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.